<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380159</url>
  </required_header>
  <id_info>
    <org_study_id>ACH443-018</org_study_id>
    <nct_id>NCT00380159</nct_id>
  </id_info>
  <brief_title>Open-Label, 48 Week Extension Study of Elvucitabine in Combination With Background ART For Subjects Who Have Completed Study ACH443-014A</brief_title>
  <official_title>An Open-Label,48 Week Extension Study of Elvucitabine Administered In Combination With Background Antiretroviral Agents in Subjects Who Have Completed 14 Days of Treatment in Protocol ACH443-014A.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety of 48 weeks of treatment with 10 mg of elvucitabine in combination with
      background ART in subjects who completed protocol ACH443-014A and meet the inclusion and
      exclusion criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label extension study for subjects who have completed 14 days of
      treatment in protocol ACH443-014A and meet all inclusion and exclusion criteria. Elvucitabine
      treatment (10mg) will begin on Day 1 (Day 15 following completion of protocol ACH443-014A)
      for all consented subjects in combination with background ART as determined by the principal
      investigator. Subjects will have clinical and laboratory assessments every 2 weeks for the
      first 8 weeks and then every 4 weeks to week 48.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety of 48weeks of 10mg/QD of elvucitabine in combination with ART</measure>
    <time_frame>September 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the anti-viral activity of elvucitabine in combination with ART as measured by plasma HIV-1 RNA over 24 weeks</measure>
    <time_frame>September 2008</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>HIV-1 Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elvucitabine</intervention_name>
    <description>elvucitabine 10 mg in combination with background ART</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have completed 14 days of treatment in ACH443-014A and who, in the
             investigator's judgment, remain candidates to receive elvucitabine together with
             background antiretroviral therapy.

        Exclusion Criteria:

          -  Failure to meet inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Saag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aids Out-Ptient Clinic University of Alabama</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Pollard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of ID University of CA Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donna Mildvan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ACTU Beth Israel Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judit Fienberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D Jayaweera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ID Research Unit University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edwin DeJesus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Immunology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melanie Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ARCA Atlanta Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ARCA</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACTU University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Salvador B Gautier Hospital</name>
      <address>
        <city>Santo Domindo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EPIMED</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>immunologische Ambulanz, University Clinic</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat zu Koln</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2006</study_first_posted>
  <disposition_first_submitted>January 20, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 20, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 13, 2014</disposition_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <name_title>Achillion Pharmaceuticals, Inc.</name_title>
    <organization>Ronald Gugliotti</organization>
  </responsible_party>
  <keyword>Extension study to ACH443-014A</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

